Get the Stockscreener App
39.51
1.52%
-0.61
Crinetics Pharmaceuticals Inc stock is traded at $39.51, with a volume of 1.09M.
It is down -1.52% in the last 24 hours and down -16.70% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
See More
Previous Close:
$40.12
Open:
$40.47
24h Volume:
1.09M
Relative Volume:
0.94
Market Cap:
$4.05B
Revenue:
$1.54M
Net Income/Loss:
$-423.10M
P/E Ratio:
-8.7142
EPS:
-4.534
Net Cash Flow:
$-356.03M
1W Performance:
-8.94%
1M Performance:
-16.70%
6M Performance:
+15.36%
1Y Performance:
+16.00%
1-Day Range:
$39.22
$40.50
1-Week Range:
$39.03
$45.18
52-Week Range:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
39.51 | 4.11B | 1.54M | -423.10M | -356.03M | -4.534 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-12-26 | Upgrade | Goldman | Neutral → Buy |
| Jul-10-25 | Initiated | Goldman | Neutral |
| Mar-25-25 | Initiated | Stifel | Buy |
| Feb-11-25 | Initiated | TD Cowen | Buy |
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Insider Sell: Stephanie Okey Sells 3,000 Shares of Crinetics Pha - GuruFocus
CRNX: Strong launch, advancing pipeline, and EU expansion position for major growth in rare endocrine diseases - TradingView
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Crinetics Pharmaceuticals (CRNX) Stock Analysis: Unpacking a 105% Potential Upside for Growth Investors - DirectorsTalk Interviews
Does Crinetics Pharmaceuticals, Inc. (CRNX) Have Momentum? - AAII
CRNX: Analyst Maintains "Market Outperform" but Lowers Price Tar - GuruFocus
Citizens Jmp Cuts Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target to $96.00 - MarketBeat
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Q4 2025 Earnings Call Transcript - Insider Monkey
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), QuidelOrtho (QDEL) and Akebia Therapeutics (AKBA) - The Globe and Mail
(CRNX) Risk Channels and Responsive Allocation - Stock Traders Daily
Crinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded at Wall Street Zen - MarketBeat
Crinetics Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CRNX) 2026-02-27 - Seeking Alpha
Vanguard Group Inc. Sells 86,003 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Palsonfi Launch Momentum And ESOP Shelf Registration Altering The Investment Case For Crinetics (CRNX)? - Yahoo Finance
Crinetics Pharmaceuticals (CRNX) TTM Loss Of US$465 Million Tests Bullish Long Term Narratives - Sahm
Crinetics Pharmaceuticals Inc (CRNX) Q4 2025 Earnings Call Highl - GuruFocus
Decoding Crinetics Pharmaceuticals Inc (CRNX): A Strategic SWOT Insight - GuruFocus
Crinetics Pharmaceuticals (CRNX) Reports Strong Q4 2025 Performa - GuruFocus
Crinetics Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Crinetics Pharmaceuticals Q4 2025 earnings beat forecasts - Investing.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS - MarketBeat
Crinetics (CRNX) Q4 2025 Earnings Call Transcript - AOL.com
Crinetics Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Crinetics (CRNX) Exceeds Revenue Expectations and Looks to Expan - GuruFocus
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Earnings Flash (CRNX) Crinetics Pharmaceuticals Posts Q4 Loss $1.29, vs. FactSet Est of $1.35 Loss - marketscreener.com
Crinetics Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Earnings Flash (CRNX) Crinetics Pharmaceuticals, Inc. Reports Q4 Revenue $6.2M, vs. FactSet Est of $4.5M - marketscreener.com
Crinetics Pharmaceuticals Reports $5.4 Million in Q4 2025 Net Revenue from PALSONIFY™ and Plans for Phase 2/3 Study of Atumelnant in 2026 - Quiver Quantitative
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - Yahoo Finance
Crinetics earnings on deck: Can drug launch offset mounting losses? - Investing.com Australia
Crinetics earnings on deck: Can drug launch offset mounting losses? By Investing.com - Investing.com South Africa
JPMorgan Chase & Co. Grows Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Inc (CRNX) Q4 2025 Earnings Call Highlights: Strong Product Launch ... By GuruFocus - Investing.com Canada
US Market Recap: Should value investors consider Crinetics Pharmaceuticals Inc2025 Price Momentum & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
[Form 4] Crinetics Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Preview: Crinetics Pharmaceuticals's Earnings - Benzinga
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis: A Potential 94% Upside Lures Investors - DirectorsTalk Interviews
Is Crinetics Pharmaceuticals (CRNX) Offering Value After Recent Share Price Pullback - Yahoo Finance
Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - StreetInsider
NEOS Investment Management LLC Reduces Stock Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals, Inc. $CRNX Shares Purchased by Skandinaviska Enskilda Banken AB publ - MarketBeat
Aberdeen Group plc Has $14.16 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Market Recap: What is the next catalyst for BTCTJuly 2025 Intraday Action & High Conviction Buy Zone Alerts - baoquankhu1.vn
Setup Watch: Should value investors consider Crinetics Pharmaceuticals IncJuly 2025 Technicals & Short-Term Swing Trade Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (CRNX) Expected to Announce Earnings on Thursday - MarketBeat
Analysts Bullish on Crinetics (CRNX) Amid Positive Clinical Trial for New Drug - Insider Monkey
Market Catalysts: Whats the beta of Crinetics Pharmaceuticals Inc stockJuly 2025 Volume & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
13 Hot Stocks to Buy with the Highest Upside Potential - Insider Monkey
Crinetics Pharmaceuticals, Inc. (CRNX): Investor Outlook With A 99% Potential Upside - DirectorsTalk Interviews
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):